Skip to main content
Log In
Sign Up
Home
Watchlist
Stocks
Stock Screener
Stock Exchanges
Comparison Tool
Earnings Calendar
By Industry
Stock Lists
Top Analysts
Top Stocks
Corporate Actions
IPOs
Recent IPOs
IPO Calendar
IPO Statistics
IPO News
IPO Screener
ETFs
ETF Screener
Comparison Tool
New Launches
ETF Providers
News
Trending
Articles
Technical Chart
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After Hours
Market Heatmap
Market Newsletter
Stock Analysis Pro
Tools
Collapse
Adaptive Biotechnologies Corporation (ADPT)
NASDAQ: ADPT · Real-Time Price · USD
Full Chart
Watchlist
Alerts
Compare
17.53
+0.75 (4.47%)
At close:
Jun 18, 2026, 4:00 PM EDT
17.70
+0.17 (0.97%)
After-hours:
Jun 18, 2026, 7:50 PM EDT
Overview
Financials
Forecast
Statistics
Metrics
History
Profile
Chart
Metrics
Revenue by Segment
Immune Medicine Revenue Breakdown
Adjusted EBITDA by Segment
MRD Revenue Breakdown
Adaptive Biotechnologies Operating Metrics
Quarterly
TTM
Download
Period Ending
Mar 31, 2026
Dec 31, 2025
Sep 30, 2025
Jun 30, 2025
Mar 31, 2025
Dec 31, 2024
Sep 30, 2024
Jun 30, 2024
Mar 31, 2024
Dec 31, 2023
Sep 30, 2023
Jun 30, 2023
Mar 31, 2023
Dec 31, 2022
Sep 30, 2022
Jun 30, 2022
Mar 31, 2022
Dec 31, 2021
Sep 30, 2021
Jun 30, 2021
Mar 31, 2021
Dec 31, 2020
Number of Clonoseq Tests Delivered
115.07K
105.59K
96.49K
88.98K
82.18K
76.11K
70.84K
66.31K
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Number of Clonoseq Tests Delivered Growth
40.01%
38.74%
36.21%
34.19%
33.72%
34.71%
37.98%
44.41%
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Revenue by Segment
Period Ending
Mar 31, 2026
Dec 31, 2025
Sep 30, 2025
Jun 30, 2025
Mar 31, 2025
Dec 31, 2024
Sep 30, 2024
Jun 30, 2024
Mar 31, 2024
Dec 31, 2023
Sep 30, 2023
Jun 30, 2023
Mar 31, 2023
Dec 31, 2022
Sep 30, 2022
Jun 30, 2022
Mar 31, 2022
Dec 31, 2021
MRD
235.71M
212.33M
190.60M
171.28M
156.62M
145.53M
136.14M
123.34M
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
MRD Growth
50.49%
45.90%
40.00%
38.87%
37.46%
41.65%
36.03%
29.33%
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Immune Medicine
59.70M
64.64M
62.16M
33.94M
32.90M
33.43M
41.14M
45.43M
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Immune Medicine Growth
81.45%
93.38%
51.09%
-25.29%
-45.67%
-50.50%
-48.32%
-51.79%
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Immune Medicine Revenue Breakdown
Period Ending
Mar 31, 2026
Dec 31, 2025
Sep 30, 2025
Jun 30, 2025
Mar 31, 2025
Dec 31, 2024
Sep 30, 2024
Jun 30, 2024
Mar 31, 2024
Dec 31, 2023
Sep 30, 2023
Jun 30, 2023
Mar 31, 2023
Dec 31, 2022
Sep 30, 2022
Jun 30, 2022
Mar 31, 2022
Dec 31, 2021
Collaboration
37.68M
41.28M
44.78M
14.55M
12.36M
13.45M
17.87M
22.37M
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Collaboration Growth
204.77%
206.88%
150.58%
-34.98%
-67.59%
-68.41%
-64.93%
-65.19%
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Immune Medicine Service
22.02M
23.36M
17.38M
19.39M
20.54M
19.98M
23.27M
23.06M
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Immune Medicine Service Growth
7.21%
16.94%
-25.31%
-15.89%
-8.37%
-19.96%
-18.79%
-23.09%
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Adjusted EBITDA by Segment
Period Ending
Mar 31, 2026
Dec 31, 2025
Sep 30, 2025
Jun 30, 2025
Mar 31, 2025
Dec 31, 2024
MRD
31.44M
15.19M
-1.79M
-14.87M
-28.08M
-41.22M
Immune
4.24M
9.16M
5.36M
-23.56M
-24.52M
-26.01M
MRD Revenue Breakdown
Period Ending
Mar 31, 2026
Dec 31, 2025
Sep 30, 2025
Jun 30, 2025
Mar 31, 2025
Dec 31, 2024
Sep 30, 2024
Jun 30, 2024
Mar 31, 2024
Dec 31, 2023
Sep 30, 2023
Jun 30, 2023
Mar 31, 2023
Dec 31, 2022
Sep 30, 2022
Jun 30, 2022
Mar 31, 2022
Dec 31, 2021
Service
211.71M
192.83M
174.10M
156.28M
144.12M
133.03M
123.64M
115.84M
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Service Growth
46.89%
44.96%
40.81%
34.91%
31.69%
29.48%
26.06%
24.07%
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Regulatory Milestone
24.00M
19.50M
16.50M
15.00M
12.50M
12.50M
12.50M
7.50M
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Regulatory Milestone Growth
92.00%
56.00%
32.00%
100.00%
177.78%
-
525.00%
275.00%
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade